A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 730 participants.
Also called NCT05462756
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 730 participants
- Sponsor
- Registry
-
NCT05462756 -
2021-005878-25
-
- Other papers using this trial's data
- Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Germany, India, Italy, Mexico, Puerto Rico, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05462756. Randomized; no masking; primary purpose treatment. Start 2022-08-11 (actual); primary completion 2024-02-27 (actual). Results posted on 2025-04-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
- Acronym
- QWINT-4
- Condition
- Type 2 Diabetes
- Condition
- Type 2 Diabetes Treated With Insulin
- Intervention (Drug)
- Insulin Efsitora Alfa
- Intervention (Drug)
- Insulin Lispro (U100)
- Intervention (Drug)
- Insulin Glargine (U100)
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05462756- Content hash
7ff40417188ac33207c812b38d9c69f60df80f7e94cd2747bac18c18074504ee